Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Growth Hormone Deficiency in 19 Major Markets
Growth Hormone Deficiency (GHD) results from the destruction of normal pituitary and hypothalamic tissue and is characterized by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland. GHD can occur at any point during an individual’s life but is primarily defined as being of childhood onset (CO) or adult onset (AO). Age at onset tends to denote a different underlying pathology for the deficiency. The majority of CO is congenital, whereas AO forms tend to be acquired or idiopathic. For congenital forms, there are three types linked with different genetic inheritance patterns. Acquired types tend to arise from a variety of tumours of the hypothalamus/pituitary as well as brain trauma, surgery/treatment of extra-cranial tumours, etc.
This report provides the current prevalent population for GHD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, GHD patients grouped by various features and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for GHD include: • Diabetes mellitus and other issues with glucose regulation (including IGT and metabolic syndrome)
• Osteopaenia, osteoporosis and increased frequency of fractures
• Liver disease
• Cerebrovascular diseases
• Cardiovascular diseases
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy • Ability to quantify patient populations in global GHD market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of GHD and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding on the impact of specific co-morbid conditions on the prevalent population of GHD patients.
• Identification of GHD patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of GHD patients.
Our reports have been used by over 10K customers, including:
The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other...
This report was created for global strategic planners who cannot be content with traditional methods of segmenting world markets. With the advent of a "borderless world", cities become a more important criteria in prioritizing markets, as opposed to regions, continents, or countries. This report covers the top 2,000 cities in over 200 countries....
381 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Bio Industry has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
The Middle East and Africa biopharmaceutical tubing market is expected to reach US$ 226.70 million by 2028 from US$ 136.34 million in 2021; it is estimated to grow at a CAGR of 7.5% from 2021 to 2028. The growth of the market is attributed to some key driving factors such as increasing elderly population in world, and rising demand...
180 pages •
By Asia Market Information & Development Company
• Aug 2021
This study focuses on China’s Biotechnology Products industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...
The biopharmaceutical tubing market is expected to reach US$ 6,013.27 million by 2028 from US$ 3,442.82 million in 2021; it is estimated to grow at a CAGR of 8.3% from 2021 to 2028. The factors increasing elderly population in world, and rising demand for minimally invasive procedures are contributing to the market growth. However, the stringent...
“Anti-CD38 antibody - Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Anti-CD38 antibody pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration,...
The oxidative stress assay market is projected to reach USD 1,326 million by 2025 from USD 836 million in 2020, at a CAGR of 9.7%. Growth in the oxidative stress assay market can be attributed to growth in the biopharmaceutical industry and increasing public-sector funding for academic research. Other important factors aiding the growth of...
The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination,...
Executive Summary Global Biologics Safety Testing Market was valued at USD 3463.90 Million in the year 2020. Major factors driving the growth of this market are the growth in pharmaceutical and biotechnology industry driven by government support, the positive trend of R&D investment in the life science sector, increasing...
Private Health Expenditure
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.